

Supplementary Information

The nickel-sirohydrochlorin formation mechanism of the ancestral class II chelatase CfbA in coenzyme F430 biosynthesis

Takashi Fujishiro,* Shoko Ogawa

Department of Biochemistry and Molecular Biology, Graduate School of Science and Engineering, Saitama University, Saitama, Japan

***Corresponding author:**

T. Fujishiro, Department of Biochemistry and Molecular Biology,
Graduate School of Science and Engineering, Saitama University,
Shimo-Okubo 255, Sakura-ku, Saitama 338-8570, Japan

Tel: +81-48-858-9293

E-mail: tfujishiro@mail.saitama-u.ac.jp

Experimental details

Materials

All chemicals, except for those described below, were purchased from Sigma-Aldrich (St. Louis, MO, USA), Nacalai Tesque (Kyoto, Japan), Wako Pure Chemicals (Osaka, Japan), or Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan) and used without further purifications. Porphobilinogen (PBG) was purchased from Frontier Scientific, Inc (Logan, UT, USA). Isopropyl- β -D-thiogalactopyranoside (IPTG) was purchased from BLD Pharmatech Inc. (Shanghai, China). The genomes of *Methanocaldococcus jannaschii* and *Methanosarcina barkeri* were obtained from RIKEN BRC through the National BioResource Project of the MEXT/AMED, Japan.

Bioinformatics

Primary amino acid sequence alignment was performed using Clustal omega¹ with the sequences of nickel-chelatase CfbA from methanogenic archaea, cobalt-chelatase CbiX⁵ from archaea with no coenzyme F430, and ferrochelatase SirB from *Bacillus subtilis* (Fig. S4). The sequence alignment figure was constructed using ESPript3.² A phylogenetic tree was created with MEGA 7.0³, utilizing the maximum-likelihood method with the JTT model, 1000 bootstrap replicates, and complete gap deletion. SirB ferrochelatase from *B. subtilis* was used as an outgroup (Fig. S5).

Construction of expression plasmids of *M. jannaschii* CfbA and its variants

The *cfbA* (MJ0970-tagged gene) was amplified from the genome of *M. jannaschii* through polymerase chain reaction (PCR) using the NcoI_MjCfbA-F and SalI_MjCfbA-R primers (Table S1). The amplified *cfbA* was incorporated into the pCDFDuet-1 vector (Novagen, Merck Millipore, Burlington, MA, USA) at the NcoI and SalI restriction sites, yielding the pCDFDuet-*cfbA* plasmid. The *M. jannaschii* CfbA H9A variant was generated using the same protocol, except for the mutagenic forward primer NcoI_MjCfbA_H9A-F (Table S1). Site-directed mutagenesis was performed to create the expression constructs for CfbA E42A and H75A variants. This involved inverse PCR using the pCDFDuet-*cfbA* plasmid as a template and the primers MjCfbA_E42A-F, MjCfbA_E42A-R, MjCfbA_H75A-F, MjCfbA_H75A-R (Table S1).

Construction of chimeric CfbA expression plasmid

A chimeric CfbA was created by substituting the His-rich region with the non-His-rich region of *M. barkeri* CfbA. First, the DNA sequence corresponding to the non-His-rich region of *M. barkeri* CfbA was amplified using the genome of *M. barkeri* as a template and the primers No_His_region_MbCfbA-F and No_His_region_MbCfbA-R (Table S1). Second, the His-rich region-encoding polynucleotides in pCDFDuet-*cfbA* was amplified via inverse PCR with the primers No_His_rich_MjCfbA_pCDF-F and No_His_rich_MjCfbA_pCDF-R. After amplification of these two gene segments, gene assembly was performed using NEB builder HiFi DNA Assembly Master Mix (New England Biolabs, Inc., Ipswich, MA, USA). The constructed plasmid was sequenced to confirm the substitution in the chimeric *cfbA*. The resulting expression plasmid for the chimeric CfbA was annotated as pCDFDuet-*chimcfbA*. The gene and amino acid sequences of the resulting chimeric *M. jannaschii* CfbA are provided as below, with a substituted His-rich region underlined.

(DNA sequence'

5'-

ATGGAAGCGTTGGTTTTAGTAGGACATGGGAGTAGATTACCCTACAGCAAAGAGCTTCTGGTAAAGTT
AGCTGAGAAAGTTAAAGAGAGAAATTTATCCCAATAGTTGAAATTGGTTTGATGGAGTTTAGTGAGC
CAACAATACCTCAAGCAGTTAAAAAAGCTATAGAACAAGGGGCTAAAAGAATCATTGTTGTTCCCTGTTT
TCTTAGCTCATGGAATTCATACAACAAGAGATATTCCAAGGTTATTGGGGTTGGACGAAAATGGCTGTG
GTACCTTGAAATTGACGGAAAAACCGTTGAAATTATATATAGAGAACCTATTGGAGCAGATGATAGAA
TTGTTGATATAATTATCGATAGAGCATTGGGAAGATA'-3'

(Amino acid sequence)

MEALVLVGHGSRPLPYSKELLVLAEKVKERNLFPIVEIGLMEFSEPTIPQAVKKAIEQGAKRIIVVPVFLAHGI

HTTRDIPRLLGLDENGCGTLEIDGKTVEIHYREPIGADDRIVDIIIDRAFGR

Expression of *M. jannaschii* wild-type, chimeric, and variant CfbA enzymes

The *Escherichia coli* C41(DE3) cells transformed with the expression plasmids of wild-type, chimeric and variant CfbA enzymes were cultivated at 37°C for 4 h in Luria-Bertani (LB) medium supplemented with 50 µg mL⁻¹ spectinomycin. At an optical density of OD₆₀₀ = 1.0, IPTG was added to the culture to a final concentration of 1 mM to induce the expression of CfbA. The cells were further cultured at 20°C for 20 h, harvested by centrifugation at 4°C at 9,000 *g* for 20 min and frozen in liquid nitrogen. The frozen cells were stored at -80 °C until further use. Attempts to express the CfbA variants (H9A, E42A, and H75A) using the same procedure for wild-type and chimeric CfbA were unsuccessful.

Purification of *M. jannaschii* wild-type CfbA

All purification steps were performed on ice or at 4°C. The frozen cells were first resuspended in buffer A (50 mM Tris-HCl buffer, pH 7.8, 500 mM KCl, and 1 mM dithiothreitol (DTT)), disrupted on ice by sonication, and then centrifuged at 4°C at 20,000 *g* for 40 min. The supernatant prepared by centrifugation of the sonicated cells was then loaded onto a HisTrap FF crude column (GE Healthcare Life Science, Chicago, IL, USA), equilibrated with buffer A. CfbA bound to the HisTrap FF crude column using its naturally occurring His-rich region. The column was then washed with buffer A and the bound CfbA was eluted with buffer B (50 mM Tris-HCl, pH 7.8, 500 mM KCl, 250 mM imidazole, and 1 mM DTT). The eluted CfbA fraction was concentrated to 5 mL using an Amicon Ultra-15 (Merck KGaA, Darmstadt, Germany). The concentrated CfbA fractions were loaded onto a Sephacryl S-200 16/60 gel filtration column (GE Healthcare Life Sciences) equilibrated with buffer C (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, and 1 mM DTT). The CfbA eluted as a homodimer, and the fractions were pooled for further use.

Purification of the chimeric CfbA

Purification of the chimeric CfbA was performed as follows: The harvested *E. coli* C41(DE3) cells were resuspended in buffer D (50 mM Tris-HCl, pH 7.8, 50 mM NaCl, 1 mM DTT) and disrupted by sonication on ice. The supernatant collected by centrifugation was heated at 80°C for 20 min. The heated solution was further centrifuged at 4°C at 20,000 *g* for 40 min to remove the precipitate. The resulting supernatant was subsequently loaded onto a HiTrap Q HP column (GE Healthcare Life Sciences), equilibrated with buffer D. The column was washed with buffer D and the chimeric CfbA was eluted with a stepwise gradient of sodium chloride ranging from 0 M to 1 M using buffer E (50 mM Tris-HCl, pH 7.8, 1 M NaCl, 1 mM DTT). The pooled chimeric CfbA fractions were concentrated and then loaded onto a Sephacryl S-200 16/60 gel filtration column equilibrated with buffer C. The chimeric CfbA also eluted as a homodimer, and the fractions were pooled for further use.

Metal content analysis of purified *M. jannaschii* wild-type and chimeric CfbA

The presence of transition metal ions in the purified wild-type CfbA fractions was analyzed using inductively coupled plasma-atomic emission spectrometry (ICP-AES) with an Optima 5300 DV system (PerkinElmer Inc., Waltham, MA, USA). Samples were prepared by heating CfbA in 3% (v/v) aqueous HNO₃ at 100°C for 10 min, and then centrifuged at 4°C at 15,000 *g* for 10 min to obtain the supernatant for ICP-AES. The standard nickel solution (Nacalai Tesque, Kyoto, Japan) was used to plot calibration curves. It should be noted that there were no metals co-purified with wild-type and chimeric CfbA.

Preparation of HemC, HemD, SirA, and SirC

HemC (porphobilinogen deaminase, BSU28150), HemD (uroporphyrinogen-III synthase, BSU28140), SirA (uroporphyrinogen-III C-methyltransferase, BSU15610; SirA is also annotated as SumT) from *B. subtilis*, as well as SirC (precorrin-2 dehydrogenase, MSBRM_0432) from *M. barkeri* were expressed and purified as *E. coli* recombinant proteins with a His-tag for use in the enzymatic preparation of sirohydrochlorin (SHC) as described previously.⁴

For the construction of HemC, HemD, and SirA expression plasmids, the corresponding *hemC*, *hemD*, and *sirA* were amplified via PCR using the *B. subtilis* genome as a template and the corresponding primers (Table S2). The amplified *hemC*, *hemD*, and *sirA* were

then ligated to pET21d vector (Novagen) at *NcoI/XhoI* restriction sites, yielding pET21d-*hemC*, pET21d-*hemD*, and pET21d-*sirA* expression vectors, respectively. The *sirC* from *M. barkeri* was also amplified via PCR using the *M. barkeri* genome as a template with corresponding primers (Table S2). The amplified *sirC* was ligated to the pACYCDuet vector (Novagen) at *BamHI/SalI* restriction sites, yielding the pACYC-*sirC* expression vector.

The expression vectors for HemC, HemD, SirA, and SirC were used for transformation of *E. coli* C41(DE3). Then, the transformed *E. coli* C41(DE3) cells were cultivated at 37°C for 4 h in LB medium supplemented with 50 µg mL⁻¹ ampicillin to express HemC, HemD, and SirA and with 25 µg mL⁻¹ chloramphenicol to express SirC. When OD₆₀₀ reached 0.8–1.0, the protein expression was induced by the addition of 1 mM IPTG, and the cells were further cultured at 20°C for 20 h. The cells were harvested by centrifugation at 4°C at 9,000 *g* for 20 min. The purification of HemC, HemD, SirA, and SirC was performed using the wild-type CfbA purification protocol described above. The purification of HemC, HemD, SirA, and SirC was confirmed via SDS-PAGE (Fig. S8).

Preparation of SHC and Ni-SHC

SHC was prepared as described previously,⁴ with some modifications. Briefly, a reaction mixture for one-pot synthesis of SHC was prepared using 0.075 mM of porphobilinogen (PBG), 0.175 mM of *S*-adenosyl-L-methionine (SAM), 0.2 mM of nicotinamide adenine dinucleotide phosphate (NADP⁺), 4 mM of MgCl₂, 2.5 µM of HemC, 2 µM of HemD, 4.2 µM of SirA, and 16 µM of SirC in 50 mM Tris-HCl, pH 8.0, under dark conditions in a Coy chamber (N₂/H₂ =95/5), at 37°C for 24 h. The reaction mixture was then anaerobically passed through a HiTrap desalting column (GE Healthcare Life Sciences), equilibrated with deionized water, to collect the fractions containing SHC. Then, the pooled SHC fractions were loaded onto a HiTrap DEAE FF column (GE Healthcare Life Sciences) equilibrated with deionized water. After washing the column with 0.2 M NaCl, bound SHC was eluted with a linear gradient of NaCl ranging from 0.2 to 1 M. The SHC fractions were pooled and evaporated in vacuo and SHC was collected. MALDI-TOF-MS of SHC was measured using an Autoflex III-2S (Bruker Corp., Billerica, MA, USA) with α-cyano-4-hydroxycinnamic acid as a matrix (Fig. S9).

For the preparation of Ni-SHC, nickel-chelatase reaction catalyzed by CfbA was anaerobically performed in 7.5 mL of reaction mixture composed of 0.038 mM SHC, 1.3 mM NiCl₂, 10 μM CfbA, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphate (TCEP) in 50 mM Tris-HCl, pH 7.8, at 37°C for 16 h in the dark in a Coy chamber (N₂/H₂ = 95/5). The reaction mixture was then passed through a HiTrap desalting column (GE Healthcare Life Sciences) to collect the fractions containing Ni-SHC. Then the pooled Ni-SHC-containing fractions were loaded onto the HiTrap DEAE FF column (GE Healthcare Life Sciences) equilibrated with deionized water. After washing the column with 0.2 M NaCl, bound Ni-SHC was eluted in a stepwise gradient of NaCl ranging from 0.2 to 1 M. Finally, the pooled Ni-SHC fractions were evaporated in vacuo, which yielded a Ni-SHC precipitate. MALDI-TOF-MS of Ni-SHC was measured with α-cyano-4-hydroxycinnamic acid as a matrix (Fig. S9).

The *in vitro* CfbA activity assay with Ni²⁺ and Co²⁺

The assay mixture was composed of 0.4 μM CfbA and 0.2 μM SHC in 50 mM Tris-HCl buffer, pH 8.0, in an anaerobic Coy chamber under N₂/H₂ = 95/5. The reaction was initiated by the addition of 5 μM NiCl₂ or CoCl₂ to the mixture of SHC and CfbA in a quartz cuvette having a 1-cm cell path. The change in UV-visible absorption at 408 nm was recorded on a NanoPhotometer C40 UV-visible spectrophotometer (Implen GmbH, Munich, Germany). The specific activities were determined by calculating the pseudo-first-order kinetic constant (k_{app}) using a non-linear least squares data-fitting to time-course changes of absorbance at 408 nm using Igor Pro 8.0 software (WaveMetrics, Inc., Lake Oswego, OR, USA) (Figs. S6, S7).

Crystallization of *M. jannaschii* wild-type and chimeric CfbA

The purified *M. jannaschii* wild-type and chimeric CfbA proteins were concentrated to 14–18 mg mL⁻¹ and 16 mg mL⁻¹, respectively, in a buffer containing 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, and 1 mM DTT. Crystallization was carried out using the sitting drop vapor diffusion method at 20°C, mixing 1 μL of the purified protein with an equivalent volume of the reservoir solution (Table S3). Crystals of the wild-type and chimeric protein appeared in two weeks and five months, respectively.

Preparation of crystals of CfbA in complex with Ni²⁺ and Co²⁺

Apo-CfbA and ligand-bound CfbA crystals (Table S3) were soaked with the ligand of interest. Ni²⁺-bound CfbA crystals were obtained by soaking apo-CfbA crystals with 0.1 mM NiCl₂ at 20°C for 1 h, followed by soaking in 0.5 mM NiCl₂ at 20°C for 30 min. The Co²⁺-bound crystals of CfbA resulted from the soaking of CfbA with 1 mM CoCl₂ at 20°C for 15 h. By contrast, the crystals of Co²⁺- and formate-bound form of CfbA was unexpectedly obtained as follows: apo-CfbA crystals were first soaked with 1 mM uroporphyrin I (Sigma-Aldrich, St. Louis, MO, USA) for 2 days, followed by soaking with 0.5 mM CoCl₂ for 10 min. Uroporphyrin I was, however, not observed in the solved CfbA structure.

Preparation of CfbA crystals with SHC and Ni-SHC

Crystals of SHC- and Ni-SHC-bound forms of CfbA were prepared by soaking apo-CfbA crystals with 4.0 mM SHC and 3.7 mM Ni-SHC, respectively, at 20°C for 15 h under anaerobic conditions.

Preparing crystals of Ni²⁺-SHC-His intermediate and Co-SHC-bound form of CfbA

To trap a reaction intermediate, we further soaked the SHC-soaked CfbA crystals described above in Ni²⁺ or Co²⁺. For Ni²⁺-soaking, the SHC-soaked CfbA crystals were soaked in 1 mM NiCl₂ at 20°C for 6.5 h and flash-frozen in liquid nitrogen. However, for Co²⁺-soaking, the crystals yielded Co-SHC bound to CfbA rather than an intermediate. For this, the SHC-soaked crystals were further soaked in 1 mM CoCl₂ at 20°C for 1 h, followed by flash-freezing in liquid nitrogen.

X-ray crystallographic analysis

X-ray diffraction data of the CfbA crystals were collected at 100 K on the Photon factory (PF) BL-17A and PF AR-NW12A beamlines (Tsukuba, Japan), and SPring-8 BL44XU beamline (Hyogo, Japan). All data sets were processed using XDS,⁵ except for the apo-CfbA, which was processed using iMOSFLM.⁶ The structures were solved using molecular replacement with Molrep⁷ or Phaser⁸ using *Archaeoglobus fulgidus* CbiX⁵ (PDB ID: 2XWS)⁹ as the search model. Models were built using Coot¹⁰ and refined using Refmac5¹¹ and Phenix¹². Model coordinates and restraints

of the ligands SHC, Co-SHC, and Ni-SHC were generated using Sketcher in CCP4¹³ and eLBOW in Phenix.¹⁴

Translation-liberation-screw-rotation refinement was also performed for the data sets of *P*2₁2₁2₁ apo-CfbA, Ni²⁺-bound CfbA, Ni-SHC-bound CfbA, and Co-SHC-bound CfbA at the final stages of modeling with TLSMD.¹⁵ The final structural models were validated using MolProbity.¹⁶ Figures containing crystal structures were created using open-source PyMOL (version 1.7, Schrödinger, LLC). The anomalous difference density maps for nickel and cobalt were calculated using the data sets collected at peak wavelengths of nickel and cobalt, respectively. Data collection, refinement statistics, and PDB IDs of the deposited models are listed in Table S4.




Fig. S1. Biosynthesis of coenzyme F430 and its related compounds. (a) Biosynthetic pathways of uroporphyrinogen III. (b) Biosynthetic pathways of siroheme, adenosylcobalamin, and coenzyme F430 via sirohydrochlorin (SHC). SirB, CbiK/CbiX, and CfbA are ferrochelatase, cobalt chelatase, and nickel chelatase, respectively.




Fig. S2. Overall structures and active sites of type II chelataases with metal ions. (a) Ni²⁺-bound CfbA (PDB ID: 6M27, this study). (b) Co²⁺- and formate-bound CfbA (PDB ID: 6M29, this study). (c) Co²⁺-bound CfbA (PDB ID: 6M28, this study). (d) Co²⁺-bound SirB (PDB ID: 5ZT7)¹⁷. (e) Co²⁺-bound CbiK (PDB ID: 2XVZ)⁴. Water molecules bound to metal ions are shown as small red spheres. Ni²⁺ is represented by green spheres and Co²⁺ by pink spheres. The side chains of conserved amino acids, formate and haem molecules are shown using sticks




Fig. S3. Overall structures and active sites of CfbA and CbiX^S. (a) Wild-type CfbA (PDB ID: 6M25, this study). (b) Chimeric CfbA (PDB ID: 6M2A, this study). (c) CbiX^S from *Archaeoglobus fulgidus* (PDB ID: 2XWQ). (d) Superimposed structures of wild-type CfbA and chimeric CfbA, and CbiX^S. The side chains of conserved amino acids are shown as sticks.

		1	10	20	30	40	50	60	
M_jannaschii_Cfba	MEALV	VGHGSR	RLPYSK	ELLVKLA	AEKVKERNLFP	I	VEIGLMEFSEPTIPQAVKKAIEQGA	KRIIVV
M_igneus_Cfba	MEALV	VGHGSR	RLPYSK	EVVEKIA	AEKIKAKNIYP	I	VEVGMMEFNEPTIPQAVKKAIEQGA	KRIIVV
M_formicicus_Cfba	MEALV	VGHGSR	RLPYSK	EVVEKIA	AEKIKAKNIYP	I	VEVGMMEFNEPTIPQAVKKAIEQGA	KRIIVV
M_maripaludis_Cfba	MEALV	VGHGSR	RLPYSK	EVVEKIA	AEKIKAKNIYP	I	VEVGMMEFNEPTIPQAVKKAIEQGA	KRIIVV
M_thermolithotrophicus_Cfba	MKNHCKNITQRRHIME	ALV	VGHGSR	RLPYSK	EVVEKIA	AEKIKAKNIYP	I	VEVGMMEFNEPTIPQAVKKAIEQGA	KRIIVV
M_kandleri_Cfba	MVAV	VGHGSR	RLPYSK	QVVEKIA	AEYVEEMGDFET	VEV	GMELCEPTVQAVKKAIEQGA	KRIIVV
M_formicicum_Cfba	MVINS	NSNSNV	GIVL	VGHGSR	RLPYKGDVLS	QLAEI	YRQ.ESSDHPVEVGMN	NKPSIPSSIN
M_stadtmanae_Cfba	MDNS	NSNSKNDT	GILL	VGHGSR	RLPYNKEVI	SATA	EKYAQT	KPDYNEVGMEL
M_marburgensis_Cfba	MDNS	NSGQTKRI	GVL	VGHGSR	RLPYGEEVI	NGIA	DIYRK.EADHPVAVG	FMNISRPSIP
M_thermautotrophicus_Cfba	MDNS	NSGQTKRI	GVL	VGHGSR	RLPYGEEVI	NGIA	DIYRK.EADHPVAVG	FMNISRPSIP
M_wolfii_Cfba	MDNS	NSGQTKRI	GVL	VGHGSR	RLPYGEEVI	NGIA	DIYRK.EADHPVAVG	FMNISRPSIP
M_fervidus_Cfba	MASN	LDQKNDI	AVL	VGHGSR	RLPYGEEVI	NGIA	DIYRK.EADHPVAVG	FMNISRPSIP
M_arvoryzae_Cfba	ME.NQKF	GILL	VGHGSR	MPYKQLI	QEVAD	KL	SKKMPDAVTRIG	FMNINRPSIP
M_conradii_Cfba	MTNQKHMSA	...K	GILL	VGHGSR	RLQYNKE	LI	TTAEEMKESGGDY	LKSCFL
M_labreanum_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_bourgenis_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_limnatis_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_petrolearia_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_mobile_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_limicola_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_formicica_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_palustris_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_hungatei_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_concillii_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_thermophila_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_methylyutens_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_evestigatum_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_mahii_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_psychrophilus_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_hollandica_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_zhilinae_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_acetivorans_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_barkeri_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_shengliensis_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
M_luminyensis_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
Ca_M_intestinalis_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
Ca_M_nitroreducens_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
Ca_S_caldarius_CfbaM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
A_fulgidus_CbIXSM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
A_shangari_CbIXSM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
S_islandicus_CbIXSM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
A_sulfidivorans_CbIXSM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL
B_subtilis_SirBM	LLVGHGSR	RLPYNKE	LI	TTAEEMKESGGDY	LKSCFL	LEYSNPTVAE	GLDL

		70	80	90
M_jannaschii_Cfba	DVFLA	HGH	TTDR	DIPRLGLIEDN
M_igneus_Cfba	DVFLA	HGH	TKRD	IPRILGLIEDDGE
M_formicicus_Cfba	DVFLA	HGH	TKRD	IPRILGLIEDDGE
M_maripaludis_Cfba	DVFLA	HGH	TKRD	IPKILGIYEGDD
M_thermolithotrophicus_Cfba	DVFLA	HGH	TKRD	IPKILGIYDGE
M_kandleri_Cfba	DVFLA	HGH	TKRD	IPKMLGLEPEWD
M_formicicum_Cfba	DVFLA	HGH	TKRD	IPRILGLI
M_stadtmanae_Cfba	DVFLA	HGH	TKRD	IPRILGLIEPVKEEP
M_marburgensis_Cfba	DVFLA	HGH	TKHD	IPHILGLD
M_thermautotrophicus_Cfba	DVFLA	HGH	TKHD	IPHILGLD
M_wolfii_Cfba	DVFLA	HGH	TKHD	IPHILGLD
M_fervidus_Cfba	DVFLA	HGH	TKHD	IPHILGLK
M_arvoryzae_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_conradii_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_labreanum_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_bourgenis_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_limnatis_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_petrolearia_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_mobile_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_limicola_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_formicica_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_palustris_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_hungatei_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_concillii_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_thermophila_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_methylyutens_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_evestigatum_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_mahii_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_psychrophilus_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_hollandica_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_zhilinae_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_acetivorans_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_barkeri_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_shengliensis_Cfba	DVFLA	HGH	TKED	IPNLGLIK
M_luminyensis_Cfba	DVFLA	HGH	TKED	IPNLGLIK
Ca_M_intestinalis_Cfba	DVFLA	HGH	TKED	IPNLGLIK
Ca_M_nitroreducens_Cfba	DVFLA	HGH	TKED	IPNLGLIK
Ca_S_caldarius_Cfba	DVFLA	HGH	TKED	IPNLGLIK
A_fulgidus_CbIXS	DVFLA	HGH	TKED	IPNLGLIK
A_shangari_CbIXS	DVFLA	HGH	TKED	IPNLGLIK
S_islandicus_CbIXS	DVFLA	HGH	TKED	IPNLGLIK
A_sulfidivorans_CbIXS	DVFLA	HGH	TKED	IPNLGLIK
B_subtilis_SirB	DVFLA	HGH	TKED	IPNLGLIK




Fig. S4. Amino acid sequence alignments. Strictly conserved amino acid residues are indicated by white letters in a red shaded box. Regions containing well-conserved amino acids are indicated by red letters in a blue framed box. His-rich regions are shown in a green framed box. Asp/Glu-rich regions interspersed in His-rich regions are also shown in a pink framed box.




Fig. S5. Phylogenetic relationships among CfbA, CbiX^S, and SirB. The clades of type I His-rich CfbA nickel chelatases (e.g., *M. jannaschii* CfbA) and type II His-deficient CfbA nickel chelatases (e.g., *M. barkeri* CfbA) were coloured in blue and red, respectively. The clades of CbiX^S cobalt chelatases from *Sulfolobales* and *Archaeoglobales* are coloured in pink and green, respectively. The bootstrap values are indicated on each branch.




Fig. S6. The *in vitro* activity assay for Ni²⁺-insertion into SHC. (a) Wild-type CfbA with Ni²⁺. (b) Chimeric CfbA with Ni²⁺. The change in absorbance over time and UV-visible spectra after the addition of Ni²⁺ or Co²⁺ to the reaction mixture was measured at 408 nm. The curves resulted from a non-linear least squares data fitting are shown as red lines for calculation of pseudo-first-order kinetic constant (k_{app}), which is described as a specific activity. The curve-fittings were calculated using Igor Pro. 8.0 software.




Fig. S7. The *in vitro* activity assay for Co²⁺-insertion into SHC. (a) Wild-type CfbA with Co²⁺. (b) Chimeric CfbA with Co²⁺. The change in absorbance over time and UV-visible spectra after the addition of Ni²⁺ or Co²⁺ to the reaction mixture was measured at 408 nm. The curves resulted from a non-linear least squares data fitting are shown as red lines for calculation of pseudo-first-order kinetic constant (k_{app}), which is described as a specific activity. The curve-fittings were calculated using Igor Pro. 8.0 software.




Fig. S8. SDS-PAGE analysis of HemC, HemD, SirA, and SirC. HemC, HemD, and SirA from *B. subtilis* with a C-terminal His₆-tag, and SirC from *M. barkeri* with an N-terminal His₆-tag were expressed recombinantly in *E. coli* and purified. Arrows indicate the bands corresponding to the purified proteins.




Fig. S9. MALDI-TOF/MS spectra. (a) Sirohydrochlorin (SHC). (b) nickel-sirohydrochlorin (Ni-sirohydrochlorin, Ni-SHC). The MS spectra were measured using α -cyano-4-hydroxycinnamic acid as a matrix.

Table S1. List of primers used for *M. jannaschii* *cfbA*.

Primer ^[a]	Sequence
NcoI_MjCfbA-F	5'-AAGGCC <u>CATGGA</u> AAGCGTTGGTTTTAGTAGGACATG-3'
Sall_MjCfbA-R	5'- CCC <u>GTCGACTT</u> TATCTTCCAATGCTCTATCGATAATTATATC AA-3'
NcoI_MjCfbA_H9A-F	5'- TATAC <u>CCATGGA</u> AAGCGTTGGTTTTAGTAGGAG <u>GCT</u> GGGAGT AGATTACCCCTACAGCAAAG-3'
MjCfbA_E42A-F	5'- <u>GCG</u> TTTAGTGAGCCAACAATACCTCAAGCAG-3'
MjCfbA_E42A-R	5'- CATCAAACCAATTTCAACTATTGGGAATAAATTTCTCTC-3'
MjCfbA_H75A-F	5'- <u>GCT</u> ACAACAAGAGATATTCCAAGGTTATTGGGG-3'
MjCfbA_H75A-R	5'-AATTCATGAGCTAAGAAAACAGGAACAACAATG-3'
No_His_rich_MjCfbA_pCDF-F	5'-GTTGAATTATATATAGAGAACCTATTGGAGCAGATG-3'
No_His_rich_MjCfbA_pCDF-R	5'-CAACCCCAATAACCTTGGGAATATCTCTTGTTG-3'
No_His_region_MbCfbA-F	5'- CCAAGGTTATTGGGGTTGGACGAAAATGGCTGTGGTAC- 3'
No_His_region_MbCfbA-R	5'- CAATAGGTTCTCTATATATAATTTCAACGGTTTTTCCGTC ATTCCAAG-3'

[a] The used restriction sites for the cloning are underlined. Codons for mutagenesis are doubly-underlined.

Table S2. List of primers used for *hemC*, *hemD*, *sirA*, and *sirC*.

Primer ^[a]	Sequence
HemC-F	5'-AAGCCATGGTGAGAACGATTAAGTAGGTTCCAGAC-3'
HemC-R	5'-AAACTCGAGTTTTCCATCCTCGTCAAGCTCCCGTTTTA -3'
HemD-F	5'-ACGACCATGGAAAATGATTTTCCGTTGAAAGGAAAAAC -3'
HemD-R	5'-GGGCTCGAGGTCGACTATTCTCTCTTCCTCTCTTGACATGCT-3'
SirA-F	5'-ATACCATGGGGAAAGTATATATTGTAGGAG -3'
SirA-R	5'-GGGCTCGAGCAACGCCTCGCTTAAATCTTGTTTTTTAGTTC -3'
SirC-F	5'- CCCGGATCCGCATATGGCTGAAACAAACAATTTTCTCCCGC-3'
SirC-R	5'- CCCCTCGAGGTCGACTCTACTGGAATTATCAAGGTAACCTGAAA-3'

[a] The used restriction sites for the cloning are underlined.

Table S3. Reservoir solutions for CfbA crystallization.

Crystal	Reservoir conditions
CfbA, $P4_1$ form	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Tris-HCl, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 7.8
CfbA, $P2_12_12_1$ form	0.2 M ammonium formate, 20% (w/v) PEG3350, pH 6.6
Ni ²⁺ -bound CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Tris-HCl, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 7.8
Co ²⁺ -bound CfbA	0.2 M L-arginine, 0.1 M MES-NaOH, 8% (w/v) γ -PGA, pH 6.5
Co ²⁺ -and formate-bound CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Tris-HCl, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 7.8
Chimeric CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Tris-HCl, 3% (w/v) γ -PGA, 10% (w/v) PEG2000MME, pH 7.8
Sirohydrochlorin (SHC)-bound CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Na-acetate, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 5.0
Nickel-sirohydrochlorin (Ni-SHC)-bound CfbA	0.3 M Na-malonate, 0.1 M Tris-HCl, 8% (w/v) γ -PGA, pH 7.8
Cobalt-sirohydrochlorin (Co-SHC)-bound CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Na-acetate, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 5.0
Catalytic intermediate Ni ²⁺ -SHC-His complex in CfbA	0.1 M ammonium sulfate, 0.3 M Na-formate, 0.1 M Na-acetate, 3% (w/v) γ -PGA, 5% (w/v) PEG3350, pH 5.0

Table S4. X-ray data collection and refinement statistics.

	CfbA, $P4_1$ form	CfbA, $P2_12_12_1$ form	Ni²⁺-bound CfbA
Data collection			
Wavelength (Å)	0.980	1.486	1.486
Space group	$P4_1$	$P2_12_12_1$	$P4_1$
Resolution (Å) ^[a]	48.47 – 2.50 (2.59 – 2.50)	46.79 – 2.61 (2.70 – 2.61)	41.47 – 2.60 (2.69 – 2.60)
Cell dimensions			
a, b, c (Å)	68.6, 68.6, 82.4	63.4, 64.4, 69.3	68.2, 68.2, 81.2
α, β, γ (°)	90.0, 90.0, 90.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Number of unique reflections ^[a]	13265 (1310)	9065 (884)	11541 (1159)
Redundancy ^[a]	2.0 (2.0)	24.2 (20.4)	19.3 (19.7)
Completeness (%) ^[a]	99.9 (99.9)	99.9 (99.9)	99.9 (100.0)
I/σ ^[a]	6.9 (2.7)	17.3 (3.2)	25.6 (4.3)
R_{merge} ^[a]	0.049 (0.199)	0.195 (0.962)	0.087 (1.030)
$CC_{1/2}$ ^[a]	0.993 (0.860)	0.998 (0.878)	0.999 (0.856)
Refinement			
Resolution (Å)	48.47 – 2.50	46.79-2.61	41.47 – 2.60
Number of reflections	13252	9063	11528
$R_{\text{work}}/R_{\text{free}}$ ^[b]	0.203 / 0.244	0.196 / 0.261	0.202 / 0.240
Rmsd bond lengths (Å) ^[c]	0.009	0.011	0.012
Rmsd bond angles (°) ^[c]	1.81	2.09	2.48
Ramachandran plot			
Favored regions (%)	94.02	94.19	92.67
Allowed regions (%)	5.13	4.56	6.03
Outlier regions (%)	0.85	1.24	1.29
PDB IDs	6M25	6M26	6M27

[a] The values in parentheses are for the highest resolution shell. [b] R_{free} was calculated as the R_{work} for 5% of the reflections, which were not included in the refinement. [c] Rmsd, root mean square deviation.

Table S4. X-ray data collection and refinement statistics. (continued)

	Co ²⁺ -bound CfbA	Co ²⁺ -bound CfbA (Co-peak data set)	Co ²⁺ - and formate-bound CfbA
Data collection			
Wavelength (Å)	1.741	1.606	1.606
Space group	<i>P4</i> ₁	<i>P4</i> ₁	<i>P4</i> ₁
Resolution (Å) ^[a]	35.14 – 3.00 (3.11 – 3.00)	35.14 – 3.34 (3.44 – 3.34)	41.70 – 2.90 (3.00 – 2.90)
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	68.1, 68.1, 82.1	68.1, 68.1, 82.1	68.4, 68.4, 82.5
<i>α</i> , <i>β</i> , <i>γ</i> (°)	90.0, 90.0, 90.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Number of unique reflections ^[a]	7543 (751)	10670 (916)	8426 (842)
Redundancy ^[a]	26.7 (23.1)	7.0 (7.0)	4.3 (4.5)
Completeness (%) ^[a]	99.5 (97.3)	99.9 (100.0)	99.1 (100.0)
<i>I</i> / <i>σ_i</i> ^[a]	34.4 (3.8)	15.7 (2.7)	11.1 (1.4)
<i>R</i> _{merge} ^[a]	0.072 (0.942)	0.083 (0.900)	0.074 (0.905)
CC _{1/2} ^[a]	1.000 (0.884)	0.999 (0.771)	0.997 (0.655)
Refinement			
Resolution (Å)	35.14 – 3.00		41.70 – 2.90
Number of reflections	7533		8419
<i>R</i> _{work} / <i>R</i> _{free} ^[b]	0.188 / 0.218		0.197 / 0.245
Rmsd bond lengths (Å) ^[c]	0.008		0.009
Rmsd bond angles (°) ^[c]	1.75		1.85
Ramachandran plot			
Favored regions (%)	91.67		94.92
Allowed regions (%)	7.89		5.08
Outlier regions (%)	0.44		0.00
PDB IDs	6M28		6M29

[a] The values in parentheses are for the highest resolution shell. [b] *R*_{free} was calculated as the *R*_{work} for 5% of the reflections, which were not included in the refinement. [c] Rmsd, root mean square deviation.

Table S4. X-ray data collection and refinement statistics. (continued)

	Chimeric CfbA	Sirohydrochlorin (SHC)-bound CfbA	Nickel-sirohydrochlorin (Ni-SHC)-bound CfbA
Data collection			
Wavelength (Å)	1.000	1.607	1.485
Space group	<i>P3₁</i>	<i>P4₁</i>	<i>P4₁</i>
Resolution (Å) ^[a]	50.0 – 2.23 (2.33 – 2.23)	48.89 – 2.60 (2.69 – 2.60)	41.59 – 2.40 (2.49 – 2.40)
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	50.2, 50.2, 90.9	69.1, 69.1, 81.7	68.2, 68.2, 82.0
α , β , γ (°)	90.0, 90.0, 120.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Number of unique reflections ^[a]	12499 (1552)	11899 (1175)	14774 (1486)
Redundancy ^[a]	9.3 (6.3)	13.7 (13.3)	13.4 (14.1)
Completeness (%) ^[a]	99.7 (97.8)	99.9 (100.0)	99.9 (100.0)
<i>I</i> / σ _{<i>I</i>} ^[a]	8.56 (1.7)	25.7 (2.9)	20.7 (3.7)
<i>R</i> _{merge} ^[a]	0.174 (0.846)	0.059 (0.977)	0.066 (0.771)
<i>CC</i> _{1/2} ^[a]	0.997 (0.832)	0.999 (0.823)	0.999 (0.894)
Refinement			
Resolution (Å)	50.0 – 2.23	48.89 – 2.60	41.59 – 2.40
Number of reflections	12484	11889	14768
<i>R</i> _{work} / <i>R</i> _{free} ^[b]	0.193 / 0.235	0.187 / 0.231	0.192 / 0.227
Rmsd bond lengths (Å) ^[c]	0.005	0.009	0.014
Rmsd bond angles (°) ^[c]	1.03	1.91	2.44
Ramachandran plot			
Favored regions (%)	89.11	93.48	92.74
Allowed regions (%)	8.06	6.52	7.26
Outlier regions (%)	2.82	0.00	0.00
PDB IDs	6M2A	6M2E	6M2F

[a] The values in parentheses are for the highest resolution shell. [b] *R*_{free} was calculated as the *R*_{work} for 5% of the reflections, which were not included in the refinement. [c] Rmsd, root mean square deviation.

Table S4. X-ray data collection and refinement statistics. (continued)

	Cobalt-sirohydrochlorin (Co-SHC)-bound CfbA	Catalytic intermediate Ni²⁺-SHC-His complex in CfbA
Data collection		
Wavelength (Å)	1.607	1.486
Space group	<i>P4</i> ₁	<i>P4</i> ₁
Resolution (Å) ^[a]	48.9 – 2.80 (2.90 – 2.80)	35.6 – 3.10 (3.21 – 3.11)
Cell dimensions		
α, b, c (Å)	69.2, 69.2, 81.8	68.9, 68.9, 83.0
α, β, γ (°)	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Number of unique reflections ^[a]	9563 (946)	7103 (707)
Redundancy ^[a]	13.5 (13.9)	12.8 (13.8)
Completeness (%) ^[a]	99.9 (100.0)	99.6 (100.0)
I/σ_I ^[a]	28.3 (3.6)	16.3 (3.1)
R_{merge} ^[a]	0.066 (0.853)	0.117 (0.917)
$CC_{1/2}$ ^[a]	0.999 (0.845)	0.998 (0.830)
Refinement		
Resolution (Å)	48.9 – 2.80	35.6 – 3.10
Number of reflections	9559	7096
$R_{\text{work}}/R_{\text{free}}$ ^[b]	0.184 / 0.212	0.173 / 0.212
Rmsd bond lengths (Å) ^[c]	0.013	0.009
Rmsd bond angles (°) ^[c]	2.11	1.83
Ramachandran plot		
Favored regions (%)	94.76	95.22
Allowed regions (%)	5.24	4.78
Outlier regions (%)	0.00	0.00
PDB IDs	6M2G	6M2H

[a] The values in parentheses are for the highest resolution shell. [b] R_{free} was calculated as the R_{work} for 5% of the reflections, which were not included in the refinement. [c] Rmsd, root mean square deviation.

References

1. F. Sievers and D. G. Higgins, *Protein Sci.*, 2018, **27**, 135–145.
2. X. Robert and P. Gouet, *Nucleic Acids Res.*, 2014, **42**, W320–324.
3. S. Kumar, G. Stecher and K. Tamura, *Mol. Biol. Evol.*, 2016, **33**, 1870–1874.
4. S. J. Moore, S. T. Sowa, C. Schuchardt, E. Deery, A. D. Lawrence, J. V. Ramos, S. Billig, C. Birkemeyer, P. T. Chivers, M. J. Howard, S. E. Rigby, G. Layer and M. J. Warren, *Nature*, 2017, **543**, 78–82.
5. W. Kabsch, *Acta Crystallogr. D Biol. Crystallogr.*, 2010, **66**, 125–132.
6. H. R. Powell, T. G. G. Battye, L. Kontogiannis, O. Johnson and A. G. W. Leslie, *Nature Protoc.*, 2017, **12**, 1310–1325.
7. A. Vagin and A. Teplyakov, *Acta Crystallogr. D Biol. Crystallogr.*, 2010, **66**, 22–25.
8. A. J. McCoy, *Acta Crystallogr. D Biol. Crystallogr.*, 2007, **63**, 32–41.
9. C. V. Romão, D. Ladakis, S. A. Lobo, M. A. Carrondo, A. A. Brindley, E. Deery, P. M. Matias, R. W. Pickersgill, L. M. Saraiva and M. J. Warren, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 97–102.
10. P. Emsley, B. Lohkamp, W. G. Scott and K. Cowtan, *Acta Crystallogr. D Biol. Crystallogr.*, 2010, **66**, 486–501.
11. A. A. Vagin, R. A. Steiner, A. A. Lebedev, L. Potterton, S. McNicholas, F. Long and G. N. Murshudov, *Acta Crystallogr. D Biol. Crystallogr.*, 2004, **60**, 2184–2195.
12. P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H. Zwart, *Acta Crystallogr. D Biol. Crystallogr.*, 2010, **66**, 213–221.
13. R. A. Nicholls, *Acta Crystallogr. D Struct. Biol.*, 2017, **73**, 158–170.
14. N. W. Moriarty, R. W. Grosse-Kunstleve and P. D. Adams, *Acta Crystallogr. D Biol. Crystallogr.*, 2009, **65**, 1074–1080.
15. J. Painter and E. A. Merritt, *Acta Crystallogr. D Biol. Crystallogr.*, 2006, **62**, 439–450.
16. C. J. Williams, J. J. Headd, N. W. Moriarty, M. G. Prisant, L. L. Videau, L. N. Deis, V. Verma, D. A. Keedy, B. J. Hintze, V. B. Chen, S. Jain, S. M. Lewis, W. B. Arendall, 3rd, J. Snoeyink, P. D. Adams, S. C. Lovell, J. S. Richardson and D. C. Richardson, *Protein Sci.*, 2018, **27**, 293–315.
17. T. Fujishiro, Y. Shimada, R. Nakamura and M. Ooi, *Dalton Trans.*, 2019, **48**, 6083–6090.